E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Alzheimer's Disease |
Enfermedad de Alzheimer |
|
E.1.1.1 | Medical condition in easily understood language |
Alzheimer's Disease (AD) is a neurodegenerative disease associated with aging. AD patients suffer from cognition deficits and memory loss as well as behavioral problems such as anxiety. |
Enfermedad de Alzheimer (EA) es una enfermedad neurodegenerativa asociada con envejecimiento. Pacientes con EA sufren déficit cognitivo, pérdida de memoria y problemas de comportamiento como ansiedad. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10001896 |
E.1.2 | Term | Alzheimer's disease |
E.1.2 | System Organ Class | 100000004852 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The purpose of this study is to evaluate the long-term safety and tolerability of JNJ 54861911 in participants in the early Alzheimer?s disease (AD [progressive brain disease that slowly destroys memory and thinking skills, and eventually even the ability to carry out the simplest tasks]) spectrum that have completed a Phase 1b or Phase 2 clinical trial with JNJ-54861911, who are willing to continue their assigned treatment. |
El objetivo de este estudio es evaluar la seguridad y tolerabilidad a largo plazo de JNJ-54861911 en participantes en el espectro de enfermedad de Alzheimer temprana (EA [enfermedad progresiva del cerebro que destruye lentamente la memoria y las habilidades de pensamiento, y, finalmente, incluso la capacidad de llevar a cabo las tareas más simples]) que hayan completado un ensayo clínico fase 1b o 2 con JNJ-54861911y que estén dispuestos a continuar con el tratamiento asignado |
|
E.2.2 | Secondary objectives of the trial |
To assess PK/PD affects and provide ongoing access to JNJ-54861911. |
Evaluar efectos FC/FD y proporcionar acceso continuado a JNJ-54861911 |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Participants in the early Alzheimer?s disease (AD) spectrum at time of enrollment under the parent protocol and according to its inclusion and exclusion criteria, must have very recently completed their treatment in a phase 1b or phase 2 JNJ-54861911 clinical study (e.g., 54861911ALZ2002) under the parent protocol. Enrollment in the extension study should be completed (Day 1 Treatment Period 1) as soon as possible, but within 6 weeks, following completion of their treatment period under the parent protocol. If not defined under the parent protocol, completion of the treatment period is defined as having completed all study related procedures of the last visit of the treatment period under the parent protocol. A screening phase of up to 12 weeks may be allowed following written approval of the Sponsor - Participant must be willing and able to adhere to the prohibitions and restrictions specified in this protocol - Each Participants (or their legally acceptable representative and caregiver depending on disease state and local requirements) must sign an informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the study and are willing to participate in the study - Participants must have a reliable informant (relative, partner, or friend). The informant must be willing to participate as a source of information and has at least weekly contact with the participant (contact can be in-person, via telephone or other audio/visual communication). The informant must have sufficient contact such that the Investigator feels he/she can provide meaningful information about the participant?s daily function. If possible, an alternate informant meeting these criteria who can replace the primary informant should be identified prior to randomization |
Los participantes en el espectro de enfermedad de Alzheimer (EA) temprana en el momento del reclutamiento con arreglo al protocolo original y conforme a sus criterios de inclusión y exclusión, tendrán que haber completado muy recientemente su tratamiento en un estudio clínico de fase 1b o fase 2 con JNJ-54861911 (p. ej., 54861911ALZ2002) con arreglo al protocolo original. El reclutamiento en el estudio de extensión tendrá que completarse (Día 1 Período de Tratamiento 1) lo antes posible, pero dentro de las 6 semanas siguientes a la finalización del período de tratamiento con arreglo al protocolo original. Si no se ha definido ya en el protocolo original, el período de tratamiento se considerará finalizado cuando se hayan completado todos los procedimientos relacionados con el estudio de la última visita del período de tratamiento con arreglo al protocolo original. La fase de selección podrá extenderse durante 12 semanas tras obtener la aprobación por escrito del promotor. -Los participantes deben ser capaces de cumplir las prohibiciones y limitaciones especificadas en este protocolo y estar dispuestos a cumplirlas. -Cada participante (o su representante legal y cuidador dependiendo del estado de su enfermedad y de los requisitos locales) deberá firmar un documento de consentimiento informado (DCI) en el que manifieste que entiende la finalidad y los procedimientos necesarios para el estudio y que está dispuesto a participar en el estudio. -Los participantes deben tener un informador fiable (familiar, pareja o amigo). El informador ha de estar dispuesto a participar como fuente de información y tener, como mínimo, un contacto semanal con el participante (el contacto podrá ser en persona, por teléfono o por comunicación audiovisual). El informador ha de tener un contacto suficiente para que el investigador considere que puede aportar información importante sobre las funciones cotidianas del participante. En la medida de lo posible, antes de la aleatorización deberá identificarse un informante suplente que cumpla estos criterios y que pueda sustituir al informante principal. |
|
E.4 | Principal exclusion criteria |
- Any condition or situation which, in the opinion of the Investigator, may put the subject at significant risk, may confound the study results, or may interfere significantly with subject?s participation in the study - The use of concomitant medications known to prolong the QT/QTc interval |
-Trastorno o situación que, en opinión del investigador, pueda suponer un riesgo importante para el paciente, confundir los resultados del estudio o interferir de forma significativa en la participación en el estudio -Uso de medicamentos concomitantes que se sabe que prolongan el intervalo QT/QTc. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs) |
Número de participantes con eventos eventos adversos (EA) o eventos adversos graves (EAG) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Day 1 up to 30 days after last dose of study drug administration |
Día 1 hasta 30 días después de la última dosis de la administración de fármaco del estudio |
|
E.5.2 | Secondary end point(s) |
1) Percent Change From Baseline in Cerebrospinal Fluid (CSF) Amyloid Beta (ABeta) (1-37, 1-38, 1-40, 1-42) Levels and Soluble Amyloid Precursor Protein (sAPP) Fragments (sAPP-alpha, sAPP-beta), Total sAPP Levels 2) Percent Change From Baseline in Plasma ABeta 1-40 Levels and sAPP Fragments (sAPP-alpha, sAPP-beta), Total sAPP Levels 3) Maximum Plasma Concentration (Cmax) of JNJ-54861911 4) Area Under the Plasma/CSF Concentration-time Curve From Time 0 to tau Hours Post Dosing (AUCtau) 5) Relationship Between Changes in CSF and Plasma ABeta Species and sAPP Fragments With Safety |
Cambio porcentual desde el momento basal en líquido cefalorraquídeo (LCR) de niveles de Beta Amiloide (ABeta) (1-37, 1-38, 1-40, 1-42) y de fragmentos (sAPP-alfa, sAPP beta)de Proteína Precursora de Amiloide soluble (sAPP), niveles totales de sAPP 2) Cambio porcentual desde el momento basal en plasma de niveles de ABeta 1-40 y fragmentos sAPP (sAPP-alfa, sAPP-beta), niveles totales de sAPP 3) Concentración plasmática máxima (Cmax) de JNJ-54861911 4) Área bajo la curva concentración-tiempo plasma/CSF desde el tiempo 0 hasta tau horas tras la dosis (AUCtau) 5) Relación entre los cambios en el LCR y plasma de especies de ABeta y fragmentos sAPP y la seguridad |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1) Day 0 and Month 12 in treatment period 1; Every 24 weeks and 96 weeks in treatment period 2 up to end of treatment visit (until registration of JNJ-54861911 or any safety issue) 2) Day 0 and Month 12 in treatment period 1; Every 24 weeks and 96 weeks in treatment period 2 up to end of treatment visit (until registration of JNJ-54861911 or any safety issue) 3) Day 0 and Month 12 in treatment period 1; Every 24 weeks and 96 weeks in treatment period 2 up to end of treatment visit (until registration of JNJ-54861911 or any safety issue) 4) Day 0 and Month 12 in treatment period 1; Every 24 weeks and 96 weeks in treatment period 2 up to end of treatment visit (until registration of JNJ-54861911 or any safety issue) 5) Day 1 up to 30 days after last dose of study drug administration |
1), 2), 3) y 4) Día 0 y Mes 12 en Período 1 de tratamiento; cada 24 y 96 semanas en Periodo 2 de tratamiento hasta visita fin tratamiento (hasta registro de JNJ-54861911 o hasta cualquier motivo de seguridad 5) Desde el Día 1 hasta 30 días después de la última dosis administrada de medicación del estudio |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Treatment period 1 is double blind; Treatment period 2 is open-label |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 5 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 7 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 22 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS |
Última visita del último paciente |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 8 |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 9 |
E.8.9.2 | In all countries concerned by the trial days | 8 |